FINWIRES · TerminalLIVE
FINWIRES

Thinkific Labs、第1四半期は赤字に転落。売上高は増加。Leigh Ramsden氏がCFOに就任。

By

-- Thinkific Labs(THNC.TO)は月曜日の取引終了後、第1四半期決算が赤字に転落したものの、売上高は増加し、リー・ラムズデン氏を最高財務責任者(CFO)に任命したと発表した。 ラムズデン氏は6月1日付で就任し、暫定CFOを務めていたケビン・ウィルソン氏の後任となる。ウィルソン氏は引き続き同社に留まり、上級財務アドバイザーの職に復帰する予定だという。 同社の純損失は110万ドル(1株当たり0.02ドル)で、前年同期の純利益40万1000ドル(1株当たり0.01ドル)から赤字に転落した。FactSetは1株当たり0.02ドルの損失を予想していた。 売上高は前年同期の1780万ドルから1870万ドルに増加した。FactSetは1860万ドルを予想していた。 「当社は第1四半期に堅調な業績を達成するとともに、研究開発チーム全体でAIを活用した重要な変革を推進しました。AIティーチングアシスタント『Thinker』のリリースに対するお客様からの反響は、当社のAI戦略への投資と方向性の正しさを証明しています。AIへの投資によって生産性が大幅に向上しており、お客様と株主の皆様への価値提供を加速できると確信しています」と、グレッグ・スミス最高経営責任者(CEO)は述べています。 第2四半期について、同社は売上高を1,820万米ドルから1,850万米ドル、調整後EBITDAをマイナス2%からマイナス5%の範囲と見込んでいます。 Thinkificの株価はトロント証券取引所で0.04カナダドル高の1.62カナダドルで取引を終えました。

Related Articles

Asia

Lottery Secures Agreement for 40-Year License Extension

Lottery (ASX:TLC) secured an agreement with the Victorian State Government for a 40-year extension of the public lottery license, according to a Tuesday filing with the Australian bourse.The license is extended to June 30, 2068, with the company paying an upfront premium of AU$1.15 billion to the state, the filing said.Historically, the license has been offered on 10-year terms and was set to expire on June 30, 2028, per the filing.

$ASX:TLC
Asia

Gentrack Group Cuts Fiscal 2026 Revenue Guidance; Plans Buyback; Kiwi Shares Fall 22%

Gentrack Group (NZE:GTK, ASX:GTK) said it now expects fiscal year 2026 revenue of between NZ$229 million and NZ$238 million, lower than its previous guidance, according to a Tuesday filing with the Australian and New Zealand bourses.The company expects fiscal year 2026 recurring revenue to grow by over 10% to around NZ$174 million. It also expects fiscal first-half revenue of around NZ$110 million, of which roughly NZ$85 million would be recurring, per the filing.Gentrack said it expects fiscal year 2026 earnings before interest, taxes, depreciation, and amortization (EBITDA) of NZ$13.5 million to NZ$20 million, and fiscal first half EBITDA of about NZ$7.8 million, both excluding acquisition costs.The guidance comes as the company has decided "to prioritize growth and global leadership over short-term EBITDA" and continues to invest in international expansion and product development, it said.The company maintained its medium-term target of a more than 15% compound annual growth rate for revenue.Additionally, after the release of fiscal first-half results, Gentrack's board plans to launch an on-market share buyback for up to 5% of the company's issued shares, per the filing.The company's Kiwi shares fell 22% in recent Tuesday trade on the New Zealand bourse.

$ASX:GTK$NZE:GTK
Research

Research Alert: CFRA Retains Buy Rating On Shares Of Vertex Pharmaceuticals Incorporated

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 results, we lower our target price to $535 from $579, 24.4x our 2027 EPS, a discount to VRTX's 10-year historical forward P/E average. We maintain our 2026 EPS view of $19.40 and our 2027 EPS estimate at $21.92. VRTX's Q1 2026 was marked by robust revenue growth, successful commercial execution of new products, and significant progress in its clinical pipeline, particularly in the renal space. The company's CF franchise remains the primary revenue driver, while new products like Casgevy and Gernavics are beginning to contribute meaningfully to growth, accounting for approximately 25% of the total product revenue growth in Q1. Pipeline advancement remains robust, in our view, with the completion of the rolling BLA submission for povetacicept in IgA nephropathy representing a significant regulatory milestone. Using a Priority Review Voucher, VRTX expects an expedited six-month FDA review timeline, which is encouraging.

$VRTX